Overview

Fragmin In The Treatment Of Acute Deep-Vein Thrombosis With Or Without Pulmonary Embolism In Cancer Patients

Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
0
Participant gender:
All
Summary
To collect postmarketing data about Fragmin safety and efficacy in the treatment of deep vein thrombosis with or without pulmonary embolism in cancer patients.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pfizer
Treatments:
Dalteparin
Heparin, Low-Molecular-Weight
Tinzaparin
Criteria
Inclusion Criteria:

- Male or female patient of 18 - 70 years of age.

- Cancer patient with proven deep-vein thrombosis with or without pulmonary embolism
confirmed by combination of clinical signs and symptoms, pulmonary hypertension on
echocardiogram, X-ray examination of the lung and eventually perfusion/ventilation
scan of the lung.

Exclusion Criteria:

- Bleeding

- Hypersensitivity to FRAGMIN® or other low-molecular weight heparins.

- Serum creatinine level > 150 umol/l.

- Platelet count of less than 100 000 per cubic millimeter at the beginning of the
therapy.

- Patient on oral anticoagulation therapy in the last 7 days.